# Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Can

Source: https://onco.cc/trials/nct06589440/  
OnCo record `nct06589440` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Botensilimab in colorectal cancer, run by Stingray Therapeutics, now recruiting.

## Summary

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) is a phase 2 interventional study registered as NCT06589440 by Stingray Therapeutics, with 70 participants planned, started 2024-11-20 and due to reach its primary completion in 2027-07-31. Interventions recorded: SR-8541A. Conditions listed: Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06589440
- Phase: 2
- Setting: Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
- Sponsor: Stingray Therapeutics
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT06589440: https://clinicaltrials.gov/study/NCT06589440

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Botensilimab](https://onco.cc/drugs/botensilimab/)

---
JSON: https://onco.cc/api/v1/entities/nct06589440.json